At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 52 enrolled
Drug / intervention
LSALT peptide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Finding Study to Evaluate the Safety and Pharmacokinetic Profile of LSALT Peptide in Healthy Participants
In Brief
A Early Phase 1 clinical trial evaluating LSALT peptide and 0.9% Saline for None - Study is to Determine Safety in Healthy Participants. Completed, enrolled 52 participants across 1 site.
Detailed Summary
A phase I double-blind, placebo-controlled, randomized, single and multiple ascending dose finding study to evaluate the safety and pharmacokinetic profile of LSALT peptide in healthy participants
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia
Collaborators--
Timeline
Early Ph 1CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartJun 2019
Primary CompletionMar 2020
TodayJul 2026
First PostedDec 11, 2018
Enrollment StartJun 27, 2019
Primary CompletionMar 31, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.6 years ago
Interventions
LSALT peptidedrug
novel 16 amino acid peptide
0.9% Salineother
saline